Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.

The serotonin (5-hydroxytryptamine) 5-HT2 receptor subfamily consists of three members, 5-HT2A, 5-HT2B, and 5-HT2C. These receptors share high homology in their amino acid sequence, have similar signaling pathways, and have been indicated to play important roles in feeding, anxiety, aggression, sexual behavior, mood, and pain. Subtype-selective agonists and antagonists have been explored as drugs for hypertension, Parkinson's disease, sleep disorders, anxiety, depression, schizophrenia, and obesity. In this study, we report the development of homogeneous agonist binding assays in a scintillation proximity assay (SPA) format to determine the high-affinity binding state of agonist compounds for the human 5-HT2C, 5-HT2A, and 5-HT2B receptors. The 5-HT2 agonist 1-(4- [125I]iodo-2,5-dimethoxyphenyl)-2-aminopropane ([125I]DOI) was used to label the high-affinity sites for the 5-HT2A and 5-HT2C receptors. The high-affinity sites for the 5-HT2B receptor were labeled with [3H]lysergic acid diethylamide. Total receptor expression was determined with the 5-HT2 antagonist [3H]mesulergine for the 5-HT2B and 5-HT2C receptors, and [3H]ketanserin for the 5-HT2A receptor. The agonist high-affinity binding sites accounted for 2.3% (5-HT(2C) receptor), 4.0% (5-HT2A receptor), and 22% (5-HT2B receptor) of the total receptor population. Competition binding studies using known agonists indicated high Z' values of the agonist binding assays in SPA format (Z' > 0.70). The Ki values of 5-HT, (R)(-)DOI, and VER-3323 for the 5-HT2A, 5-HT2B, and 5-HT2C receptors by SPA format were equivalent to published data determined by filtration binding assays. These results indicate that agonist binding assays in SPA format can be easily adapted to a high throughput assay to screen for selective 5-HT2C receptor agonists, as well as for selectivity profiling of the compounds.

[1]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[2]  J. Slightom,et al.  A unique phenotype of 5‐HT2C, agonist‐induced GTPγ35S binding, transferable to 5‐HT2A and 5‐HT2B, upon swapping intracellular regions , 2003, British journal of pharmacology.

[3]  J. Leysen,et al.  5-HT2 receptors. , 2004, Current drug targets. CNS and neurological disorders.

[4]  D. Harmer,et al.  5‐HT2B receptors play a key role in mediating the excitatory effects of 5‐HT in human colon in vitro , 2002, British journal of pharmacology.

[5]  N. Maclean,et al.  Pyrrolo[3,2,1-ij]quinoline derivatives, a 5-HT2c receptor agonist with selectivity over the 5-HT2a receptor: potential therapeutic applications for epilepsy and obesity. , 2000, Bioorganic & medicinal chemistry letters.

[6]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[7]  B. Largent,et al.  High‐Affinity Agonist Binding Correlates with Efficacy (Intrinsic Activity) at the Human Serotonin 5‐HT2A and 5‐HT2C Receptors: Evidence Favoring the Ternary Complex and Two‐State Models of Agonist Action , 1999, Journal of neurochemistry.

[8]  A. Lawrence,et al.  Characterisation of agonist binding on human 5-HT2C receptor isoforms. , 2001, European journal of pharmacology.

[9]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[10]  J. Lachowicz,et al.  WGA-coated yttrium oxide beads enable an imaging-based adenosine 2a receptor binding scintillation proximity assay suitable for high throughput screening. , 2004, Assay and drug development technologies.

[11]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[12]  M. Millan,et al.  Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  B. Roth,et al.  Molecular biology of serotonin receptors structure and function at the molecular level. , 2002, Current topics in medicinal chemistry.

[14]  K. Crane,et al.  Development of a homogeneous binding assay for histamine receptors. , 2004, Analytical biochemistry.

[15]  R. Emeson,et al.  Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.

[16]  Brian M. Smith,et al.  Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity. , 2005, Bioorganic & medicinal chemistry letters.

[17]  R. Schreiber,et al.  (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  M. Sasamata,et al.  Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats , 2004, Brain Research.

[19]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[20]  T. Okabe,et al.  High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. , 2004, Assay and drug development technologies.

[21]  C. Niswender,et al.  Serotonin 5‐HT2C Receptor RNA Editing Alters Receptor Basal Activity , 1999, Journal of neurochemistry.

[22]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[23]  R. Glennon,et al.  Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors , 1998, Psychopharmacology.

[24]  V. Setola,et al.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.

[25]  G. Kennett,et al.  Indoline derivatives as 5-HT(2C) receptor agonists. , 2004, Bioorganic & medicinal chemistry letters.

[26]  J. Leysen,et al.  Serotonin-S2 receptor binding sites and functional correlates , 1984, Neuropharmacology.

[27]  A. Sleight,et al.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[28]  T. Gray,et al.  5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells , 2001, The Journal of Neuroscience.

[29]  M. Bickerdike.  5-HT2C receptor agonists as potential drugs for the treatment of obesity. , 2003, Current topics in medicinal chemistry.

[30]  Daniel Hoyer,et al.  Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.

[31]  B. Harrison,et al.  Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. , 2004, Bioorganic & Medicinal Chemistry Letters.

[32]  R. Porter,et al.  Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.

[33]  J. Leysen,et al.  Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. , 1985, The Journal of biological chemistry.

[34]  Colleen M. Niswender,et al.  RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.

[35]  A. Serretti,et al.  The 5-HT2C receptor as a target for mood disorders , 2004, Expert opinion on therapeutic targets.

[36]  A. Smith,et al.  A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. , 1999, Analytical biochemistry.

[37]  B. Harrison,et al.  WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[38]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[39]  Thermogenic effect of YM348, a novel 5‐HT2C‐receptor agonist, in rats , 2004, The Journal of pharmacy and pharmacology.

[40]  G. Kennett,et al.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[41]  D. Middlemiss,et al.  Pharmacological characterisation of human 5-HT2 receptor subtypes. , 2001, European journal of pharmacology.

[42]  V. Jaakola,et al.  Development of a scintiplate assay for recombinant human α2B-adrenergic receptor , 2002 .